Document:

ex_144203.htm

 

Exhibit 10.2(b)

ASSIGNMENT AND ASSUMPTION AGREEMENT

 

This Assignment and Assumption Agreement (“Assignment”) is made by and between MID AMERICA BANK & TRUST COMPANY, a Missouri state-chartered bank, having its principal location in Dixon, Missouri (“Bank”), Atlanticus Services Corporation (“Atlanticus”), a Georgia Corporation, and THE BANK OF MISSOURI, a Missouri state-chartered bank having its principal location in Perryville, Missouri, (“Assignee”)

 

 

WHEREAS, Assignee has purchased and otherwise acquired Bank, and Bank is thereafter expected to dissolve its charter as of March 23, 2018 (the “Acquisition”);

 

WHEREAS, Bank has ongoing contractual relationships with Atlanticus in the form of a Program Management Agreement entered on or about April 1, 2017 and all prior versions thereto (collectively the “Agreements”);

 

WHEREAS, Assignee, as part of the Acquisition, desires to accept the assignment of the Agreements and to assume the Bank’s obligations under the Agreements;

 

WHEREAS, Atlanticus, Bank and Assignee, desire to execute a writing approving and otherwise confirming the acceptance, assignment and assumption of the Agreements;

 

NOW, THEREFORE, in consideration of the mutual covenants and agreements herein set forth, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties covenant and agree as follows:

 

1. Effective as of 12:01 a.m., Central Standard Time March 24, 2018 (the “Effective Date”), Bank assigns to Assignee all of its right, title and interest in and to the Agreements and Atlanticus accepts assignment and assumption of the Agreements.

 

  2. Bank covenants, warrants and represents that:

 

 (a)     The Agreements are in full force and effect;

(b)     Bank has full right and power to execute this Assignment; and

(c)     The Agreements have not been modified, supplemented or amended, except as provided herein.

 

3. Atlanticus covenants, warrants and represents that:

 

	 	
			(a)

				
			The Agreements are in full force and effect;

			

	 	
			(b)

				
			Atlanticus has full right and power to execute this Assignment; and

			

	
			 

			 

				
			(c)

				
			The Agreements have not been modified, supplemented or amended, except as provided herein.

			

 

4.      Bank hereby surrenders and assigns to Assignee and Assignee hereby accepts the surrender and assignment from Bank, all of Bank’s right, title and interest in, to and under the Agreements.

 

5. Assignee hereby assumes and agrees to be bound by all, terms, covenants and conditions which, pursuant to the Agreements, are to be observed, kept and/or performed by the Bank, as of the Effective Date.

 

6. Atlanticus consents to the aforesaid Assignment by Bank to Assignee.

 

7. Nothing in this Assignment shall be deemed to authorize any Assignment or other transfer in whole or in part of the interest of the Assignee in violation of any provision of the Agreements.

 

8. This Assignment shall be binding and shall inure to the benefit of the parties hereto and their successors and permitted assigns.

 

9.  This Assignment may be executed in counterparts.

 

 

 

 

[SIGNATURE PAGES FOLLOW]

 

 

 

 

 

 

 

IN WITNESS WHEREOF, the parties have caused this Amendment to be executed as of the Effective Date indicated above.

 

MID AMERICA BANK & TRUST COMPANY

 

By:     /s/Gregory J. Luehmann

Name:     Gregory J. Luehmann

Title:     President/CEO-Mid America Bank and Trust Co.

Date:     3-23-18

 

ATLANTICUS SERVICES CORPORATION

 

By:     /s/Rosalind T. Drakeford

Name:     Rosalind T. Drakeford

Title:     Secretary

Date:     3-29-18

 

 

BANK OF MISSOURI

 

By:     /s/Martha J. Rollet

Name:     Martha J. Rollet

Title:     Executive Vice President

Date:     3-23-18ex_144204.htm

 

Exhibit 10.2(c)

 

ASSIGNMENT AND ASSUMPTION AGREEMENT

 

This Assignment and Assumption Agreement (“Assignment”) is made by and between MID AMERICA BANK & TRUST COMPANY, a Missouri state-chartered bank, having its principal location in Dixon, Missouri (“Bank”), FORTIVA FUNDING, LLC, (“FORTIVA”), a Georgia limited liability company, and THE BANK OF MISSOURI, a Missouri state-chartered bank having its principal location in Perryville, Missouri, (“Assignee”)

 

WHEREAS, Assignee has purchased and otherwise acquired Bank, and Bank is thereafter expected to dissolve its charter as of March 23, 2018 (the “Acquisition”);

 

WHEREAS, Bank has ongoing contractual relationships with Fortiva in the form of an Receivables Sale Agreement and an Amended and Restated Receivables Sale Agreement executed on or about April 1, 2017 (collectively the “Agreements”);

 

WHEREAS, Assignee, as part of the Acquisition, desires to accept the assignment of the Agreements and to assume the Bank’s obligations under the Agreements;

 

WHEREAS, Fortiva, Bank and Assignee, desire to execute a writing approving and otherwise confirming the acceptance, assignment and assumption of the Agreements;

 

NOW, THEREFORE, in consideration of the mutual covenants and agreements herein set forth, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties covenant and agree as follows:

 

1. Effective as of 12:01 a.m., Central Standard Time March 24, 2018 (the “Effective Date”), Bank assigns to Assignee all of its right, title and interest in and to the Agreements and Fortiva accepts assignment and assumption of the Agreements.

 

  2. Bank covenants, warrants and represents that:

 

(a)     The Agreements are in full force and effect;

 

(b)     Bank has full right and power to execute this Assignment; and

 

(c)     The Agreements have not been modified, supplemented or amended, except as provided herein.

 

3. Fortiva covenants, warrants and represents that:

 

	 	
			(a)

				
			The Agreements are in full force and effect;

			

 

	 	
			(b)

				
			Fortiva has full right and power to execute this Assignment; and

			

 

	 	
			(c)

				
			The Agreements have not been modified, supplemented or amended, except as provided herein.

			

 

4.      Bank hereby surrenders and assigns to Assignee and Assignee hereby accepts the surrender and assignment from Bank, all of Bank’s right, title and interest in, to and under the Agreements.

 

5. Assignee hereby assumes and agrees to be bound by all, terms, covenants and conditions which, pursuant to the Agreements, are to be observed, kept and/or performed by the Bank, as of the Effective Date.

 

6. Fortiva consents to the aforesaid Assignment by Bank to Assignee.

 

7. Nothing in this Assignment shall be deemed to authorize any Assignment or other transfer in whole or in part of the interest of the Assignee in violation of any provision of the Agreements.

 

8. This Assignment shall be binding and shall inure to the benefit of the parties hereto and their successors and permitted assigns.

 

9.  This Assignment may be executed in counterparts.

 

 

 

 

 

 

[SIGNATURE PAGES FOLLOW]

 

 

 

 

 

 

 

IN WITNESS WHEREOF, the parties have caused this Amendment to be executed as of the Effective Date indicated above.

MID AMERICA BANK & TRUST COMPANY

 

By:         /s/Gregory J. Luehmann

Name:     Gregory J. Luehmann

Title:       President/CEO-Mid America Bank and Trust Co.

Date:       3-21-18

 

FORTIVA FUNDING, LLC

 

By:        /s/ Brian Stone

Name:   Brian Stone

Title:     Chief Risk Officer

Date:     3-30-18

 

 

BANK OF MISSOURI

 

By:     /s/Adrian O. Breen

Name:Adrian O. Breen

Title:   CEO

Date:   3-22-18life-ex102_52.htm

aTyr Pharma

Brave Science, Meaningful Medicines

 

 

 

 

 

 

Exhibit 10.2

 

October 7, 2014

 

 

 

Ms. Nancy Krueger, Esq. 288 Ocean View Avenue Del Mar, CA 92014

 

Dear Nancy,

 

This letter is a formal offer setting forth the principal terms for you to join aTyr Pharma, Inc. ("aTyr" or the "Company"), a Delaware corporation, which is located in San Diego, California.

 

Position:Vice President, Legal Affairs (October 7, 2014 through October 7, 2015) Location:San Diego, CA

	
 
	
Status:           
	
Full-Time, exempt through the close of the initial public offering of the Company's common stock (Project Stellar). Following the closure of Project Stellar and the legal work associated with this project, your time will transition to Part-Time through October 7, 2015 at which time your role will terminate with the Company unless renewed terms are negotiated.
	
 

 

Reporting to:             The Chief Financial Officer

 

Base Salary Rate: $10,000.00 semi-monthly (which equals $240,000.00 per year) less applicable withholdings, paid in accordance with Company's normal payroll practices during your Full-Time employment. This rate will change to $5,416.65 semi-monthly when your role transitions to Part­ Time. Future adjustments in compensation, if any, will be made by the Company in its sole and absolute discretion.

 

	
 
	
Equity:
	
Shortly after commencement of your employment with the Company, and subject to approval by the board of directors, you will be granted an option to purchase 283,232 shares of the Common Stock of the Company (the "Initial Option") pursuant to the Company's 2014 Stock Plan (the "aTyr Plan"). Subject to your continued employment with the Company, the shares subject to the Initial Option shall vest monthly in equal installments over a six (6) year period.
	
 

 

 

 

 

aTyr Pharma, Inc.

3545 John Hopkins Court, Suite #250   Son Diego   CA   92 121

Phone 858 73 1 8389   Fox 858 731 8394

 

WEST\246499936.1

 
 

aTyr Pharma

Brave Science, Meaningful Medicines

 

 

 

 

 

 

 

 

 

Ms. Nancy Krueger, Esq.

October 7, 2014 Page two

 

The exercise price per share of the Option shall be the fair market value of the Common Stock, as determined by the board of directors at the time the Option is granted. The specific terms and conditions of your Option will be subject to the terms of the 2014 Stock Plan, as well as the terms set forth in a Stock Option Agreement between you and the Company. This Stock Option Agreement will be entered into and executed after you commence your employment with the Company. The vesting of the shares subject to the Option will be subject to acceleration in full if your employment with the Company is terminated by the Company (or any successor thereto) without Cause (as defined in the aTyr Plan) within twelve (12) months following a Change in Control (as defined in the aTyr Plan).

 

	
 
	
Benefits:
	
You will be entitled to receive standard medical, life and dental insurance benefit s for yourself and your dependents in accordance with Company policy as long as you work 30 or more hours per week on a consistent basis.  Company reserves the right to change or eliminate these benefits on a prospective basis at any time.
	
 

 

	
 
	
40 l(k) Plan:
	
You will be eligible to participate in the aTyr Pharma, Inc. 401(k) Savings Plan immediately following the start of your employment.
	
 

 

Vacation &

	
 
	
Sick Time:
	
You will be entitled to accrue 15 days of vacation per year as a Full-Time employee and then on a prorated basis as a Part-Time Employee. You will have 6 days of sick time available each year.
	
 

 

Holidays:You will be eligible for aTyr's paid holidays.  The schedule is published

prior to the beginning of each calendar year.

 

Employment at Will: Your employment will be at-will, which means it may be terminated at any time by you or the Company for any reason, with or without cause, and that your employment is not for any specific period of time. Any change to the at-will employment relationship must be by a specific, written agreement signed by you and the Company's Chief Executive Officer.

 

aTyr Pharma, Inc.

3545 John Hopkins Court, Suite #250   San Diego   CA   92121 Phone 858 73 1 8389    Fax 858 731 8394

 

 

WEST\246499936.   1

 
 

aTyr Pharma

Brave Science, Meaningful Medicines

 

 

 

 

 

 

 

Ms. Nancy Krueger, Esq.

October 7, 2014

Page three

 

 

Start Date:October 7, 2014 or a mutually agreed upon date.

As a condition of your employment, you will be required to sign and abide by our Employee Nondisclosure and Assignment Agreement (the "Employee NDA") when you begin your employment.   A copy is attached for your reference.   As a condition of your employment, you will also be required to abide by the Company's code of conduct and other policies applicable to employees as set forth in the Company's employee handbook in effect from time to time.   A copy will be made available to you during your employment.   In addition, in order to comply with the Immigration Reform and Control Act of 1986, within three (3) days of your Start Date you will be required to provide sufficient documentation to verify your identity and legal authorization to work in the United States. Please bring with you on your Start Date, the original of one of the documents noted in List A or one document from List B and one document from List C as itemized in the enclosed "Lists of Acceptable Documents".   If you do not have the originals of any of these documents, please contact me immediately.

In the event of any dispute or claim relating to or arising out of your employment relationship with the Company, this agreement, or the termination of your employment with the Company for any reason (including, but not limited to, any claims of breach of contract, defamation, wrongful termination or age, sex, sexual orientation, race, color, national origin, ancestry, marital status, religious creed, physical or mental disability or medical condition or other discrimination, retaliation or harassment) , you and the Company agree that all such disputes shall be fully resolved by confidential, binding arbitration conducted by a single arbitrator through the American Arbitration Association ("AAA") under the AAA's National Rules for the Resolution of Employment Disputes then in effect, which are available online at the AAA's website at www.adr.org. The arbitrator shall permit adequate discovery and is empowered to award all remedies otherwise available in a court of competent jurisdiction and any judgment rendered by the arbitrator may be entered by any court of competent jurisdiction. By executing this letter, you and the Company are both waiving the right to a jury trial with respect to any such disputes. Company shall bear the costs of the arbitrator, forum and filing fees. Each party shall bear its own respective attorney fees and all other costs, unless otherwise provided by law and awarded by the arbitrator.

It is aTyr's policy to respect fully the rights of your previous employers in their proprietary or confidential information. No employee is expected to disclose, or is allowed to use for aTyr's purposes, any confidential or proprietary information he or she may have acquired as a result of previous employment.

 

 

aTyr Pharma, Inc.

3545 John Hopkins Court, Suite #250   San Diego   CA   92121 Phone 858 73 1 8389    Fax 858 731 8394

 

 

WEST\246499936.   1

 
 

aTyr Pharma

Brave Science, Meaningful Medicines

 

 

 

 

 

 

Ms. Nancy Krueger, Esq. October 7, 2014

Page four

 

 

I am pleased to extend this offer to you and look forward to your acceptance. Please sign and return the enclosed copy of this offer letter as soon as possible to indicate your agreement with the terms of this offer.  This offer will lapse if not signed and returned by October 7, 2014.

 

Once signed by you, this letter, together with the Employee NDA, will constitute the complete agreement between you and the Company regarding employment matters and will supersede all prior written or oral agreements or understandings on these matters.

 

Our mission is to discover life-changing therapies with relentless determination for people with grave maladies where others fall short. I believe you will be able to make an immediate contribution to this mission and I think you will enjoy the rewards of working for an innovative, fast-paced company.  One of the keys to our success is top people.  We hope you accept our offer to be one of those people.

 

Yours sincerely,

 

 

/s/ John Mendlein

John Mendlein, Ph.D.

Executive Chairman and Chief Executive Officer Enclosures

 

I accept the terms of employment as described in this offer letter dated October 7, 2014 and will start my employment on October 4, 2014.   I confirm that by my start date at aTyr Pharma, Inc. I will be under no contract or agreement with any other entity which would in any way restrict my ability to work at aTyr Pharma, Inc. or perform the functions of my job for aTyr, including, but not   limited to, any employment agreement and/or non-compete agreement.

 

		
	
/s/ Nancy Krueger
	
Date 10/7/14

	
Ms. Nancy Krueger, Esq.
	
 

 

aTyr Pharma, Inc.

3545 John Hopkins Court, Suite #250   San Diego   CA   92121 Phone 858 73 1 8389    Fax 858 731 8394

 

 

WEST\246499936.   1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}]]